Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DVIY25
|
|||
| Drug Name |
CTX130
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | T-cell lymphoma [ICD-11: 2A90; ICD-10: C81-C86] | Phase 1 | [1] | |
| Company |
CRISPR Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | CD70 antigen (CD27-L) | Target Info | . | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| TNFalpha Signaling Pathway | ||||
| RANKL Signaling Pathway | ||||
| Reactome | TNFs bind their physiological receptors | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04502446) A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of CRISPR Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.